Want to see BYSI full AI Analyst Report?
Top Page
Beyondspring
(NASDAQ:BYSI)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:07/10/26
The score is primarily constrained by weak financial fundamentals (minimal revenue, ongoing cash burn, and negative shareholder equity), with additional pressure from a technically weak price trend below major moving averages. Valuation signals are limited due to negative earnings and no dividend support, while the recent leadership overhaul is a modest positive catalyst but not enough to offset the core balance-sheet and funding risks.
Positive Factors
Leadership upgrade
A targeted leadership refresh brings a CEO with capital-markets and regional partner experience and a CFO with listed-company finance background. Over the next 2–6 months this materially improves execution capacity for a Phase 3 program and strengthens investor and partner engagement.
Negative Factors
Negative shareholder equity
A materially negative equity base signals cumulative losses and asset depletion, constraining borrowing capacity and corporate flexibility. Structurally this weakens the balance sheet, can deter counterparties and complicate capital raises or M&A, raising long-term solvency and dilution risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Leadership upgrade
A targeted leadership refresh brings a CEO with capital-markets and regional partner experience and a CFO with listed-company finance background. Over the next 2–6 months this materially improves execution capacity for a Phase 3 program and strengthens investor and partner engagement.
Read all positive factors
Beyondspring (BYSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.99M
Dividend YieldN/A
Average Volume (3M)478.07K
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.24K
Enterprise Value/Ebitda-7.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Beyondspring Business Overview & Revenue Model
Company Description
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced th...
How the Company Makes Money
null...
Beyondspring Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.35M | 1.35M |
| Gross Profit | -19.00K | -87.00K | 0.00 | -302.00K | 1.35M | 1.35M |
| EBITDA | -8.02M | -8.54M | -8.48M | -13.62M | -34.96M | -64.49M |
| Net Income | -7.64M | -7.99M | -11.12M | -21.03M | -33.28M | -64.18M |
Balance Sheet | ||||||
| Total Assets | 18.41M | 25.93M | 34.31M | 24.81M | 46.22M | 81.65M |
| Cash, Cash Equivalents and Short-Term Investments | 7.86M | 12.56M | 2.92M | 15.34M | 37.27M | 72.37M |
| Total Debt | 246.00K | 320.00K | 589.00K | 847.00K | 4.96M | 3.58M |
| Total Liabilities | 48.76M | 49.92M | 48.60M | 48.27M | 49.23M | 60.73M |
| Stockholders Equity | -34.49M | -32.16M | -32.90M | -26.80M | -5.98M | 26.68M |
Cash Flow | ||||||
| Free Cash Flow | -19.09M | -20.07M | -16.67M | -16.57M | -28.18M | -50.09M |
| Operating Cash Flow | -19.09M | -20.02M | -16.44M | -16.47M | -28.15M | -47.24M |
| Investing Cash Flow | 12.07M | 13.48M | -12.01M | -100.00K | 18.25M | -20.41M |
| Financing Cash Flow | -2.13M | 2.27M | 26.79M | 4.00K | 3.43M | 1.00K |
Beyondspring Technical Analysis
Negative
1.66
Price Trends
1.57
Negative
1.59
Negative
1.68
Negative
Market Momentum
-0.11
Positive
30.95
Neutral
18.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.57, and below the 200-day MA of 1.68, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 30.95 is Neutral, neither overbought nor oversold. The STOCH value of 18.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BYSI.
Beyondspring Risk Analysis
Beyondspring disclosed 87 risk factors in its most recent earnings report. Beyondspring reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beyondspring Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $347.10M | -0.81 | -94.90% | ― | -71.26% | -300.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $50.99M | -6.53 | 23.76% | ― | ― | ― | |
47 Neutral | $69.53M | -2.81 | -201.43% | ― | ― | 33.86% | |
45 Neutral | $31.20M | -10.44 | -92.03% | ― | -100.00% | -170.04% | |
44 Neutral | $26.36M | >-0.01 | -198.48% | ― | -0.46% | 96.28% | |
44 Neutral | $323.36M | -3.83 | -118.24% | ― | 138.86% | 42.14% |
* Healthcare Sector Average
BYSI
Beyondspring
1.13
-0.74
-39.57%
PSTV
Plus Therapeutics
3.82
-8.43
-68.82%
XFOR
X4 Pharmaceuticals
3.70
2.20
146.33%
ABVC
ABVC BioPharma
1.18
-1.89
-61.56%
PRLD
Prelude Therapeutics
3.93
3.01
331.32%
GANX
Gain Therapeutics
1.84
0.16
9.52%
Beyondspring Corporate Events
Business Operations and StrategyExecutive/Board Changes
BeyondSpring Announces Major Leadership Transition and New CEO
Positive
Jun 4, 2026
On June 4, 2026, BeyondSpring announced a leadership overhaul effective July 1, 2026, as founder and current CEO Dr. Lan Huang steps down from the chief executive role to remain as chair, while concentrating her operational efforts at SEED Therape...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.